Fosså SD - Search Results

1

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence.

Hernes E, Fosså SD, Berner A, Otnes B, Nesland JM. Hernes E, et al. Among authors: fossa sd. Br J Cancer. 2004 Jan 26;90(2):449-54. doi: 10.1038/sj.bjc.6601536. Br J Cancer. 2004. PMID: 14735192 Free PMC article.

2

Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

Fosså SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Fosså SD, et al. J Clin Oncol. 1992 Apr;10(4):569-73. doi: 10.1200/JCO.1992.10.4.569. J Clin Oncol. 1992. PMID: 1312586

3

Rare and unusual tumors of the genitourinary tract.

Fosså S. Fosså S. Curr Opin Oncol. 1992 Jun;4(3):463-8. doi: 10.1097/00001622-199206000-00006. Curr Opin Oncol. 1992. PMID: 1323334 Review.

4

Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment.

Fosså SD, Paus E, Lindegaard M, Newling DW. Fosså SD, et al. Br J Urol. 1992 Feb;69(2):175-9. doi: 10.1111/j.1464-410x.1992.tb15491.x. Br J Urol. 1992. PMID: 1371425

5

Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies.

Fosså SD, Lehne G, Gunderson R, Hjelmaas U, Holdener EE. Fosså SD, et al. Int J Cancer. 1992 Apr 1;50(6):868-70. doi: 10.1002/ijc.2910500606. Int J Cancer. 1992. PMID: 1372881 Clinical Trial.

6

89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.

Fosså SD, Paus E, Lochoff M, Backe SM, Aas M. Fosså SD, et al. Br J Cancer. 1992 Jul;66(1):177-80. doi: 10.1038/bjc.1992.238. Br J Cancer. 1992. PMID: 1379058 Free PMC article.

7

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.

Fosså SD, Waehre H, Paus E. Fosså SD, et al. Br J Cancer. 1992 Jul;66(1):181-4. doi: 10.1038/bjc.1992.239. Br J Cancer. 1992. PMID: 1379059 Free PMC article.

8

Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer.

Waehre H, Wanderaas EH, Paus E, Fosså SD. Waehre H, et al. Among authors: fossa sd. Eur Urol. 1992;22(1):33-8. doi: 10.1159/000474718. Eur Urol. 1992. PMID: 1385143

9

Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party).

Fosså SD, Harland SJ, Kaye SB, Raghavan D, Russell JM, Parmar MK, Uscinska BM, Wood R. Fosså SD, et al. Br J Urol. 1992 Aug;70(2):161-8. doi: 10.1111/j.1464-410x.1992.tb15696.x. Br J Urol. 1992. PMID: 1393439 Clinical Trial.

10

DNA flow cytometry and neo-adjuvant chemotherapy/radiotherapy in operable muscle-invasive bladder carcinoma. A preliminary report.

Jacobsen AB, Berner A, Juul M, Ous S, Pettersen EO, Fosså SD. Jacobsen AB, et al. Among authors: fossa sd. Eur Urol. 1992;22(4):316-22. doi: 10.1159/000474779. Eur Urol. 1992. PMID: 1490510

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results